NO20090415L - JAK inhibitorer for behandling av myeloproliferative forstyrrelser - Google Patents

JAK inhibitorer for behandling av myeloproliferative forstyrrelser

Info

Publication number
NO20090415L
NO20090415L NO20090415A NO20090415A NO20090415L NO 20090415 L NO20090415 L NO 20090415L NO 20090415 A NO20090415 A NO 20090415A NO 20090415 A NO20090415 A NO 20090415A NO 20090415 L NO20090415 L NO 20090415L
Authority
NO
Norway
Prior art keywords
treatment
myeloproliferative disorders
jak inhibitors
mammal
condensed pyrrolocarbazole
Prior art date
Application number
NO20090415A
Other languages
English (en)
Inventor
Pawel Dobrzanski
Bruce A Ruggeri
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20090415L publication Critical patent/NO20090415L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen tilveiebringer en fremgangsmåte for behandling av myeloproliferative lidelser, myelodysplastiske syndromer og andre sykdommer, hvor aktivering av JAK2 bidrar til patologi, hos et pattedyr omfattende administrering til pattedyret en effektiv mengde av et kondensert pyrrolokarbazolderivat hvor det kondenserte pyrrolokarbazolderivatet hemmer aktiviteten til JAK2.
NO20090415A 2006-07-21 2009-01-28 JAK inhibitorer for behandling av myeloproliferative forstyrrelser NO20090415L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83262706P 2006-07-21 2006-07-21
US11/880,063 US20080021013A1 (en) 2006-07-21 2007-07-19 JAK inhibitors for treatment of myeloproliferative disorders
PCT/US2007/016513 WO2008011174A2 (en) 2006-07-21 2007-07-20 Jak inhibitors for treatment of myeloproliferative disorders

Publications (1)

Publication Number Publication Date
NO20090415L true NO20090415L (no) 2009-02-20

Family

ID=38814536

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090415A NO20090415L (no) 2006-07-21 2009-01-28 JAK inhibitorer for behandling av myeloproliferative forstyrrelser

Country Status (13)

Country Link
US (1) US20080021013A1 (no)
EP (1) EP2046340B1 (no)
JP (1) JP5340931B2 (no)
KR (1) KR101399180B1 (no)
AU (1) AU2007275562B2 (no)
BR (1) BRPI0715196A2 (no)
CA (1) CA2658192C (no)
ES (1) ES2437317T3 (no)
IL (1) IL196517A (no)
MX (1) MX2009000713A (no)
NO (1) NO20090415L (no)
NZ (1) NZ574212A (no)
WO (1) WO2008011174A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8460240B2 (en) * 2006-08-07 2013-06-11 W. L. Gore & Associates, Inc. Inflatable toroidal-shaped balloons
US20080125711A1 (en) * 2006-08-07 2008-05-29 Alpini Alfred A Catheter balloons with integrated non-distensible seals
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
AU679752B2 (en) * 1993-05-28 1997-07-10 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
CA2299471C (en) * 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
DE69812177T2 (de) * 1997-12-31 2004-01-15 Cephalon Inc 3'-epi k-252a derivate
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20060281700A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
JP5249772B2 (ja) * 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
CN101365704A (zh) * 2005-12-09 2009-02-11 艾博特公司 来妥替尼晶形1、结晶来妥替尼无水化物和非晶形来妥替尼

Also Published As

Publication number Publication date
MX2009000713A (es) 2009-03-04
JP5340931B2 (ja) 2013-11-13
WO2008011174A3 (en) 2008-03-06
EP2046340A2 (en) 2009-04-15
BRPI0715196A2 (pt) 2013-11-12
JP2009544700A (ja) 2009-12-17
ES2437317T3 (es) 2014-01-10
CA2658192A1 (en) 2008-01-24
IL196517A (en) 2015-08-31
HK1127301A1 (en) 2009-09-25
KR20090035596A (ko) 2009-04-09
NZ574212A (en) 2011-12-22
IL196517A0 (en) 2009-11-18
WO2008011174A2 (en) 2008-01-24
EP2046340B1 (en) 2013-09-04
AU2007275562B2 (en) 2013-10-31
CA2658192C (en) 2016-05-24
KR101399180B1 (ko) 2014-05-27
US20080021013A1 (en) 2008-01-24
AU2007275562A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
NO20090415L (no) JAK inhibitorer for behandling av myeloproliferative forstyrrelser
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
BRPI0410905A (pt) inibidores de p-38
EA200802054A1 (ru) Ингибиторы фермента
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
UA94129C2 (ru) Соединения для ингибирования митоза
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EA201170521A1 (ru) Новые соединения
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
DK3135672T3 (da) Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application